By Fineline Cube The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released two draft proposals establishing criteria for when drugs manufactured in China by foreign originator companies may retain their status as Reference Listed Drugs (RLDs) following a change in Marketing Authorization Holder (MAH). The proposals, open for public comment for one month, aim to ensure continued access to high-quality generic drugs while maintaining regulatory consistency with international standards.
Regulatory Proposal Overview
| Item | Detail |
|---|---|
| Issuing Authority | Center for Drug Evaluation (CDE), NMPA |
| Proposal Documents | 1. “Situations in Which Drugs Manufactured in China by Foreign Originator Companies May Be Selected as Reference Listed Drugs Following a Change in Marketing Authorization Holder (draft proposal)” 2. “Requirements for Reference Listed Drug Application Materials Following a Change in Marketing Authorization Holder for Drugs Manufactured in China by Foreign Originator Companies (draft proposal)” |
| Public Comment Period | One month from publication date |
| Primary Objective | Ensure high-quality generic drug availability through consistent RLD selection criteria |
| Regulatory Philosophy | Originator drugs preferred as RLDs, including locally manufactured versions |
Key Eligibility Criteria for RLD Retention
Following a change in MAH for locally manufactured originator RLDs, the drug may retain RLD status under three specific circumstances:
- Corporate Continuity: The MAH before and after the change belong to the same parent company
- Manufacturing Consistency: The drug continues to be manufactured by the original originator manufacturer after the MAH change
- International Regulatory Alignment: The new MAH belongs to the same parent company as the MAH in regulatory-established major countries or regions (United States, Europe, or Japan)
Market Impact & Pharmaceutical Industry Implications
- Generic Drug Development: Clear RLD retention criteria provide stability for generic manufacturers investing in bioequivalence studies
- M&A Activity Support: Framework accommodates pharmaceutical industry consolidation while protecting public health interests
- International Harmonization: Alignment with US, EU, and Japanese regulatory approaches facilitates global drug development strategies
- Quality Assurance: Emphasis on manufacturing continuity ensures consistent product quality for RLD reference purposes
- Regulatory Certainty: Defined criteria reduce ambiguity in RLD selection decisions following corporate transactions
- Market Access: Maintains pathway for high-quality generics to enter Chinese market through established originator references
Strategic Outlook
The CDE’s proposed framework represents a pragmatic approach to balancing pharmaceutical industry dynamics with public health protection. By establishing clear, objective criteria for RLD retention following MAH changes, the proposals support both innovation and generic competition. The emphasis on international regulatory alignment reflects China’s ongoing efforts to harmonize its pharmaceutical regulatory system with global standards, potentially facilitating faster market access for multinational pharmaceutical companies while ensuring Chinese patients continue to receive high-quality generic alternatives.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory implementation and industry impacts. Actual outcomes may differ based on final regulatory decisions, industry feedback during the comment period, and evolving regulatory priorities.-Fineline Info & Tech